Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 11
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Cognitive Decline and BPSD Are Concomitant with Autophagic and Synaptic Deficits Associated with G9a Alterations in Aged SAMP8 Mice

  • Vasilopoulou, Foteini
  • Bellver-Sanchis, Aina
  • Companys-Alemany, Júlia
  • Jarne-Ferrer, Júlia
  • Irisarri, Alba
  • Palomera-Ávalos, Verónica
  • Gonzáez-Castillo, Celia
  • Ortuño-Sahagún, Daniel
  • Sanfeliu, Coral
  • Pallàs, Mercè
  • Griñán-Ferré, Christian
Behavioural and psychological symptoms of dementia (BPSD) are presented in 95% of Alzheimer’s Disease (AD) patients and are also associated with neurotrophin deficits. The molecular mechanisms leading to age-related diseases are still unclear; however, emerging evidence has suggested that epigenetic modulation is a key pathophysiological basis of ageing and neurodegeneration. In particular, it has been suggested that G9a methyltransferase and its repressive histone mark (H3K9me2) are important in shaping learning and memory by modulating autophagic activity and synaptic plasticity. This work deepens our understanding of the epigenetic mechanisms underlying the loss of cognitive function and BPSD in AD. For this purpose, several tasks were performed to evaluate the parameters of sociability (three-chamber test), aggressiveness (resident intruder), anxiety (elevated plus maze and open field) and memory (novel object recognition test) in mice, followed by the evaluation of epigenetic, autophagy and synaptic plasticity markers at the molecular level. The behavioural alterations presented by senescence-accelerated mice prone 8 (SAMP8) of 12 months of age compared with their senescence-accelerated mouse resistant mice (SAMR1), the healthy control strain was accompanied by age-related cognitive deficits and alterations in epigenetic markers. Increased levels of G9a are concomitant to the dysregulation of the JNK pathway in aged SAMP8, driving a failure in autophagosome formation. Furthermore, lower expression of the genes involved in the memory-consolidation process modulated by ERK was observed in the aged male SAMP8 model, suggesting the implication of G9a. In any case, two of the most important neurotrophins, namely brain-derived neurotrophic factor (Bdnf) and neurotrophin-3 (NT3), were found to be reduced, along with a decrease in the levels of dendritic branching and spine density presented by SAMP8 mice. Thus, the present study characterizes and provides information regarding the non-cognitive and cognitive states, as well as molecular alterations, in aged SAMP8, demonstrating the AD-like symptoms presented by this model. In any case, our results indicate that higher levels of G9a are associated with autophagic deficits and alterations in synaptic plasticity, which could further explain the BPSD and cognitive decline exhibited by the model., This study was supported by the Ministerio de Economía, Industria y Competitividad (Agencia Estatal de Investigación, AEI) and Fondo Europeo de Desarrollo Regional (MINECO-FEDER) by the grants PDC2021-121096/AEI/10.13039/501100011033 and PID2020-118127RB-I00 funded by MCIN/AEI/10.13039/501100011033, and 2017SGR106 and 2019LLAV00017 from AGAUR.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Neuroprotective Epigenetic Changes Induced by Maternal Treatment with an Inhibitor of Soluble Epoxide Hydrolase Prevents Early Alzheimer′s Disease Neurodegeneration

  • Bartra Cabré, Clara
  • Irisarri Martínez, Marta
  • Villoslada, Ainhoa
  • Corpas, Rubén
  • Aguirre Infantes, Samuel
  • García-Lara, Elisa
  • Suñol, Cristina
  • Pallàs, Mercè
  • Griñán-Ferré, Christian
  • Sanfeliu, Coral
Modulation of Alzheimer′s disease (AD) risk begins early in life. During embryo development and postnatal maturation, the brain receives maternal physiological influences and establishes epigenetic patterns that build its level of resilience to late-life diseases. The soluble epoxide hydrolase inhibitor N-[1-(1-oxopropyl)-4-piperidinyl]-N′-[4-(trifluoromethoxy)phenyl] urea (TPPU), reported as ant-inflammatory and neuroprotective against AD pathology in the adult 5XFAD mouse model of AD, was administered to wild-type (WT) female mice mated to heterozygous 5XFAD males during gestation and lactation. Two-month-old 5XFAD male and female offspring of vehicle-treated dams showed memory loss as expected. Remarkably, maternal treatment with TPPU fully prevented memory loss in 5XFAD. TPPU-induced brain epigenetic changes in both WT and 5XFAD mice, modulating global DNA methylation (5-mC) and hydroxymethylation (5-hmC) and reducing the gene expression of some histone deacetylase enzymes (Hdac1 and Hdac2), might be on the basis of the long-term neuroprotection against cognitive impairment and neurodegeneration. In the neuropathological analysis, both WT and 5XFAD offspring of TPPU-treated dams showed lower levels of AD biomarkers of tau hyperphosphorylation and microglia activation (Trem2) than the offspring of vehicle-treated dams. Regarding sex differences, males and females were similarly protected by maternal TPPU, but females showed higher levels of AD risk markers of gliosis and neurodegeneration. Taken together, our results reveal that maternal treatment with TPPU impacts in preventing or delaying memory loss and AD pathology by inducing long-term modifications in the epigenetic machinery and its marks., This research was funded by the Spanish Ministerio de Ciencia e Innovación and the Agencia Estatal de Investigación (MCIN/AEI/10.13039/501100011033, grants PID2019-106285RB and PDC2021-121096) and by the European Union “NextGenerationEU”/PRTR; CSIC (2019AEP038); CERCA program/Generalitat de Catalunya; and 2017SGR106 from AGAUR.
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

High levels of anti-inflammatory epoxyeicosatrienoic acids may improve neurodevelopment in children prenatally exposed to mercury

  • Sanfeliu, Coral
  • Bartra Cabré, Clara
  • Llop, Sabrina
  • Kuligowski, Julia
  • Albiach-Delgado, Abel
  • Suñol, Cristina
  • Rodríguez-Farré, Eduard
  • Ballester, Ferrán
  • Soler-Blasco, Raquel
  • Jora, Beatrice
  • Jarné-Ferrer, Júlia
  • Griñán-Ferré, Christian
  • Vázquez, Santiago
  • Pallàs, Mercè
Trabajo presentado en Neuroscience 2023, celebrado en Washington D. C. (Estados Unidos), del 11 al 15 de noviembre de 2023, A balanced concentration of polyunsaturated fatty acids (PUFA) in the prenatal stage is essential for children¿s neurodevelopment. Also, animal studies showed that high levels of anti-inflammatory PUFA metabolites in the embryonic brain protect against genetic or environmental insults that would otherwise cause cognitive impairment. Here we used liquid chromatography - mass spectrometry to analyze oxylipins, the oxygenated metabolites of PUFA, in the placenta tissue (N=12) and cord blood plasma (N=39) of children from the INMA cohort (Valencia, Spain). Both tissues were characterized for total Hg levels as a reference for developmental neurotoxic MeHg exposure during pregnancy and distributed in low and high Hg groups. Deleterious effects of high Hg were confirmed in the placenta as decreased proteasome activity and inhibitory epigenetic changes. Children¿s neurodevelopment was assessed using the Bayley (14 months) and McCarthy (5 years) scales. Spearman correlation coefficients were calculated between scores and oxylipin levels. We also analyzed cortical brain tissue from wild type and transgenic Alzheimer's disease (5XFAD) mice dosed for 2 months with vehicle or a soluble epoxide hydrolase enzyme (sEH) inhibitor, UB-BJ-02 (5 mg/Kg, N=5/group). Inhibition of sEH increases levels of the potent anti-inflammatory epoxyeicosatrienoic acids (EETs) by inhibiting their hydrolysis to dihydro-EETs (DiHETs). We found that DiHETs were increased in the placenta of high Hg group. Furthermore, the mental and psychomotor development of 14-month-old children correlates positively with DiHETs levels in both placenta and cord blood tissues. Interestingly, cord blood DiEHTs positively correlate with working memory at 5 years. Thus we suggest that higher levels of DiHETs indicate higher synthesis of their anti-inflammatory EETs precursors. Accordingly, placenta levels of EETs correlate with mental development at 14 months of age. Other oxylipin changes also suggested an involvement of inflammatory mechanisms in the neurodevelopment of children exposed to MeHg. In general, higher levels of markers of resolved inflammation or final stable metabolites in the placenta and cord blood tissues correlate with better neuropsychological development in children exposed to environmental MeHg. Finally, mouse treatment with the drug UB-BJ-02 showed increased EETs and decreased pro-inflammatory markers in brain tissue. Both human and experimental results showed that EETs are prominent anti-inflammatory metabolites and support sEH inhibition as an anti-inflammatory treatment to increase brain resilience to environmental risk of neurodevelopmental damage., Spanish Ministerio de Ciencia e Innovación and the Agencia Estatal de Investigación (MCIN/AEI/10.13039/501100011033, grants PID2019-106285RB, PID2020-118127RB and PDC2021-121096); European Union “NextGenerationEU”/PRTR; CERCA program/Generalitat de Catalunya; 2021-SGR-357 from AGAUR; H2020 874583; FIS/FEDER 19/1338; 16/1288; AICO/2020/285; CIAICO/2021/132; MS20/0006; MS21/0133
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Soluble epoxide hydrolase inhibitors counteract microglia pro-inflammatory response induced by monomeric C-reactive protein

  • Bartra Cabré, Clara
  • Vuraić, Kristijan
  • Yuan, Yi
  • Valdés-Quiroz, Haydeé
  • Codony, Sandra
  • Sawkulycz, Xenia
  • Slevin, Mark
  • Vázquez, Santiago
  • Suñol, Cristina
  • Sanfeliu, Coral
Neuroinflammation is a crucial neuropathological trait in Alzheimer’s disease (AD), although its role in the development of AD is not clarified. We previously proposed the monomeric C-reactive protein (mCRP), which is generated by activation and further disaggregation of circulating CRP, as a trigger of AD neuropathology after cerebrovascular damage. mCRP is a potent pro-inflammatory agent found deposited in AD brain tissue and proved to induce AD-like dementia and tau and amyloid neuropathology when injected into mouse hippocampus [1]. Furthermore, treatment of pregnant mice with TPPU, an inhibitor of the soluble epoxide hydrolase enzyme (sEH) with anti-inflammatory properties, successfully prevented memory loss and AD pathology in the offspring by inducing long-term modifications in the epigenetic machinery [2]., Spanish Ministerio de Ciencia e Innovación and Agencia Estatal de Investigación (MCIN/AEI/10.13039/501100011033, grants PID2019-106285RB, PID2020-118127RB-I00 and PDC2021-121096); CSIC (2019AEP038); CERCA program/Generalitat de Catalunya; and 2021-SGR-00357 from AGAUR., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

New insights in animal models of neurotoxicity-induced neurodegeneration

  • Sanfeliu, Coral
  • Bartra Cabré, Clara
  • Suñol, Cristina
  • Rodríguez-Farré, Eduard
The high prevalence of neurodegenerative diseases is an unintended consequence of the high longevity of the population, together with the lack of effective preventive and therapeutic options. There is great pressure on preclinical research, and both old and new models of neurodegenerative diseases are required to increase the pipeline of new drugs for clinical testing. We review here the main models of neurotoxicity-based animal models leading to central neurodegeneration. Our main focus was on studying how changes in neurotransmission and neuroinflammation, mainly in rodent models, contribute to harmful processes linked to neurodegeneration. The majority of the models currently in use mimic Parkinson's disease (PD) and Alzheimer's disease (AD), which are the most common neurodegenerative conditions in older adults. AD is the most common age-related dementia, whereas PD is the most common movement disorder with also cases of dementia. Several natural toxins and xenobiotic agents induce dopaminergic neurodegeneration and can reproduce neuropathological traits of PD. The literature analysis of MPTP, 6-OH-dopamine, and rotenone models suggested the latter as a useful model when specific doses of rotenone were administrated systemically to C57BL/6 mice. Cholinergic neurodegeneration is mainly modelled with the toxin scopolamine, which is a useful rodent model for the screening of protective drugs against cognitive decline and AD. Several agents have been used to model neuroinflammation-based neurodegeneration and dementia in AD, including lipopolysaccharide (LPS), streptozotocin, and monomeric C-reactive protein. The bacterial agent LPS makes a useful rodent model for testing anti-inflammatory therapies to halt the development and severity of AD. However, neurotoxin models might be more useful than genetic models for drug discovery in PD but that is not the case in AD where they cannot beat the new developments in transgenic mouse models. Overall, we should work using all available models, either in vivo, in vitro, or in silico, considering the seriousness of the moment and urgency of developing effective drugs., This research was funded by the Spanish Ministerio de Ciencia e Innovación and the Agencia Estatal de Investigación (MCIN/AEI/10.13039/501100011033, grants PID2019-106285RB and PDC2021-121096) and by the European Union “NextGenerationEU”/PRTR; CERCA program/Generalitat de Catalunya; and 2021-SGR-00357 from AGAUR., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Resveratrol Activates Antioxidant Protective Mechanisms in Cellular Models of Alzheimer’s Disease Inflammation

  • Bartra Cabré, Clara
  • Yuan, Yi
  • Vuraić, Kristijan
  • Valdés-Quiroz, Haydeé
  • García-Baucells, Pau
  • Slevin, Mark
  • Pastorello, Ylenia
  • Suñol, Cristina
  • Sanfeliu, Coral
Resveratrol is a natural phenolic compound with known benefits against neurodegeneration. We analyzed in vitro the protective mechanisms of resveratrol against the proinflammatory monomeric C-reactive protein (mCRP). mCRP increases the risk of AD after stroke and we previously demonstrated that intracerebral mCRP induces AD-like dementia in mice. Here, we used BV2 microglia treated with mCRP for 24 h in the presence or absence of resveratrol. Cells and conditioned media were collected for analysis. Lipopolysaccharide (LPS) has also been implicated in AD progression and so LPS was used as a resveratrol-sensitive reference agent. mCRP at the concentration of 50 µg/mL activated the nitric oxide pathway and the NLRP3 inflammasome pathway. Furthermore, mCRP induced cyclooxygenase-2 and the release of proinflammatory cytokines. Resveratrol effectively inhibited these changes and increased the expression of the antioxidant enzyme genes Cat and Sod2. As central mechanisms of defense, resveratrol activated the hub genes Sirt1 and Nfe2l2 and inhibited the nuclear translocation of the signal transducer NF-ĸB. Proinflammatory changes induced by mCRP in primary mixed glial cultures were also protected by resveratrol. This work provides a mechanistic insight into the protective benefits of resveratrol in preventing the risk of AD induced by proinflammatory agents., This research was funded by Spanish MCIN/AEI/10.13039/501100011033, grant PID2019-106285RB-C22; MCIN/AEI/10.13039/501100011033 and EU Next Generation Funds/RTRP, grant PDC2021-121096-C22; AGAUR, Catalonia, grant 2021SGR357; the CERCA Programme/Generalitat de Catalunya; and Noi inhibitori ai proteinei C-reactive și blocanți de disociere pentru uz terapeutic în bolile cardiovasculare–CREDICARD, Contractului de finanțare nr. PCE 60/2021, cod proiect: PN-III-P4-ID-PCE-2020-1540., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Novel molecular mechanism driving neuroprotection after soluble epoxide hydrolase inhibition: Insights for Alzheimer's disease therapeutics

  • Griñán-Ferré, Christian
  • Jarné-Ferrer, Júlia
  • Bellver-Sanchís, Aina
  • Codony, Sandra
  • Puigoriol-Illamola, Dolors
  • Sanfeliu, Coral
  • Oh, Yumin
  • Lee, Seulki
  • Vázquez, Santiago
  • Pallàs, Mercè
Neuroinflammation is widely recognized as a significant hallmark of Alzheimer's disease (AD). To combat neuroinflammation, the inhibition of the soluble epoxide hydrolase (sEH) enzyme has been demonstrated crucial. Importantly, sEH inhibition could be related to other neuroprotective pathways described in AD., This work was supported by Spanish Ministerio de Ciencia e Innovación (PID2019-106285/AEI/10.13039/501100011033; PDC2021-121096/AEI/10.13039/501100011033; María de Maeztu Unit of Excellence to Institute of Neurosciences, University of Barcelona, MDM-2017-0729) and 2021SGR357 (AGAUR, Catalonia). ABS acknowledges a FI SDUR (2021 FI-B0812) fellowship to AGAUR Catalonia., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

Overcoming Pain Management: Unlocking the Power of Dual-Mechanism Compounds

  • Escriche, Celia
  • Sánchez, Javier
  • Pujol, Eugènia
  • Martínez-López, juan
  • Brea, José Manuel
  • Morisseau, Christophe
  • Pérez, Belén
  • Bartra Cabré, Clara
  • Sanfeliu, Coral
  • Hammock, Bruce D.
  • Loza, María Isabel
  • Vázquez, Santiago
Trabajo presentado en el 4th Molecules Medicinal Chemistry Symposium: Harnessing the Power of New Drug Modalities, celebrado en Barcelona del 24 al 26 de abril de 2024, This work was funded by the Grants PID2020-118127RB-I00, to S.V., and PID2021-121096-C22, to C.S., funded by MICIU/AEI/10.13039/501100011033 and by “European Union NextGenerationEU/PRTR”, and the Xunta de Galicia (ED431G 2019/02 and ED431C 2018/21) to M.I.L. C.E.M. and J.S. thank the Spanish MICIU for PhD Grants (FPI program). Partial support was provided by NIH-NIEHS River Award R35 ES03443, NIH-NIEHS Superfund Program P42 ES004699, NINDS R01 DK107767, and NIDDK R01 DK103616 to B.D.H, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Novel Soluble Epoxide Hydrolase Inhibitor: Toward Regulatory Preclinical Studies

  • Jarne-Ferrer, Júlia
  • Sánchez, Javier
  • Codony, Sandra
  • Schneider, Marion
  • Müller, Christa E.
  • Sanfeliu, Coral
  • Franco, Rafael
  • Vazquez, Santiago
  • Griñán-Ferré, Christian
  • Pallàs, Mercè
Neuroinflammation is widely recognized as a key pathological hallmark of Alzheimer's disease (AD). Recently, inhibiting soluble epoxide hydrolase (sEH) has emerged as a promising therapeutic strategy for AD. sEH plays a pivotal role in neuroinflammation by hydrolyzing epoxyeicosatrienoic acids (EETs), which have anti-inflammatory and neuroprotective properties, into pro-inflammatory dihydroepoxyeicosatrienoic acids (DHETs). Furthermore, the overexpression of the enzyme in the brains of AD patients and animal models of the disease highlights its relevance as a therapeutic target. Our previous studies, using the inhibitor UB-SCG-51 demonstrated that sEH inhibition regulates neuroinflammation and other mechanisms, such as the unfolded protein response pathway, while reducing autophagy, apoptosis, and neuronal death, thereby promoting neuroprotection. Building on these findings, we evaluated the arginine salt of the compound, designated UB-SCG-74, which offers improved oral absorption compared to that of UB-SCG-51 while retaining high permeability, potency, and selectivity. In experiments using 5XFAD mice, UB-SCG-74 treatment significantly improved cognition and synaptic plasticity, outperforming donepezil, a standard AD drug, and ibuprofen, an anti-inflammatory drug. Remarkably, these benefits persisted for 4 weeks after administration cessation, suggesting lasting therapeutic effects. Safety pharmacology studies showed no toxicity, supporting the advancement of UB-SCG-74 into preclinical regulatory evaluation. Our findings further indicate that sEH inhibition engages multiple neuroprotective pathways, potentially modifying both AD symptoms and disease progression, thus reinforcing its therapeutic potential., This study was supported by the Ministerio de Economía, Industria y Competitividad (Agencia Estatal de Investigación, AEI) and European Union NextGenerationEU/PRTR (PID2020-118127RB-I00/AEI/10.13039/501100011033 to S.V.; PDC2021-121096/AEI/10. 13039/501100011033 to M.P./C.S. PID2021-127693OB-I00 AEI/10.13039/501100011033 to C.G., PID2021-138079OB-I00 AEI/10.13039/501100011033 to M.P.), and Generalitat de Catalunya (2021 SGR 00357). J.S. was supported by the Research Personnel Training Program (FPI grant PRE2021-099446) of the Spanish Ministerio de Ciencia, Innovación y Universidades (MICIU), and Agencia Estatal de Investigación (AEI). C.G.F. and M.P. belong to María de Maeztu Unit of Excellence (Institute of Neurosciences, University of Barcelona, CEX2021-001159-M, Ministry of Science and Innovation). C.E.M. is grateful for support by the Deutsche Forschungsgemeinschaft (DFG) within the Major Research Instrumentation scheme for a highly sensitive HPLC-MS instrument (QTRAP). The paid version of Biorender.com was utilized to prepare the illustrations, Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Dimethoxybenzohomoadamantane-based soluble epoxide hydrolase inhibitors: in vivo efficacy in a murine model of chemotherapy-induced neuropathic pain

  • Codony, Sandra
  • Jora, Beatrice
  • Santos-Caballero, Miriam
  • Qiu, Qiongju
  • Calvó-Tusell, Carla
  • Escriche, Celia
  • Turcu, Andreea L.
  • Prischi, Filippo
  • Bartra, Clara
  • Val, Cristina
  • Morisseau, Christophe
  • Pérez, Belén
  • Bertran-Mostazo, Andrea
  • Osuna, Sílvia
  • Corpas, Rubén
  • Griñán-Ferré, Christian
  • Galdeano, Carles
  • Loza, M. Isabel
  • Pallàs, Mercè
  • Sanfeliu, Coral
  • Hammock, Bruce D.
  • Brea, José
  • Feixas, Ferran
  • Conte, Maria R.
  • Cobos, Enrique J.
  • Vázquez, Santiago
The soluble epoxide hydrolase (sEH) has recently emerged as a promising target for the treatment of several pain-related conditions. Herein, we report the design and synthesis of a peripherally restricted sEH inhibitor with high potency and good Drug Metabolism and Pharmacokinetics (DMPK) properties. Molecular dynamics and X-ray crystallography helped reveal the binding of these inhibitors to sEH. The selected compound showed a robust analgesic effect in a dose-dependent manner in a murine model of chemotherapy-induced neuropathic pain (CINP). Moreover, the compound also prevented the development of paclitaxel-induced neuropathic pain. Overall, these results suggest that peripheral inhibition of sEH might constitute a novel therapy to prevent and treat CINP., this work was funded by the spanish Ministerio de ciencia, innovación y universidades, Miciu/aei/10.13039/501100011033: Grants PiD2020-118127RB-i00 and PiD2023-147004OB-i00 (to s.V.), PiD2019-108691RB-i00 (to e.J.c.),PDc2021-121096 (to M.P. and c.s.), PiD2021-127693OB-i00 (to c.G.), PiD2022-141676NB-i00 (to F.F.);PiD2021-129034NB-i00 and PDc2022-133950-i00 (to s.O.); the Generalitat de catalunya (2021 sGR 00357 and 2021sGR 00487); the european Research council (eRc-2015-stG-679001-NetMoDezyme and eRc-2022-coG-101088032 tos.O.); the Xunta de Galicia (eD431c 2022/20); and the european Regional Development Fund (eRDF); Ministry ofscience and innovation, spain, with funds from the european union NextGenerationeu (PRtRc17.i1) and theautonomous community of Galicia within the framework of the 2023 Biotechnology Plan applied to health (to M.i.l.and J.B.). Partial support was provided by Nih-Niehs River award R35 es030443 and, Nih-Niehs superfund ProgramP42 es004699 to B.D.h. the content is solely the responsibility of the authors and does not necessarily represent theofficial views of the National institutes of health. M.R.c. was granted access to i24 beamline by the Diamond lightsource for (proposal number: MX32787). s.c. and a.l.t. received PhD fellowships from the universitat de Barcelona(aPiF grant) and the spanish Ministerio de educación, cultura y Deporte (FPu15/00889 grant), respectively. a.B.-M.,c.e., and M.s.-c. were supported by the Research Personnel training Program (FPi grants PRe2019-087468,PRe2022-104952, and PRe2020-096203, respectively) of the spanish Ministerio de ciencia, innovación y universidades(Miciu) and agencia estatal de investigación (aei). Q.Q. is funded by the King’s-china scholarship council PhDscholarship programme. F.F. received spanish MiciNN for a Ramón y cajal fellowship (RYc2020-029552-i). c.c.-t.received science Postdoctoral Fellowship from a schmidt Futures program., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Datos de investigación Set de datos (Dataset)

Dimethoxybenzohomoadamantane-based soluble epoxide hydrolase inhibitors: in vivo efficacy in a murine model of chemotherapy-induced neuropathic pain [Dataset]

  • Codony, Sandra
  • Jora, Beatrice
  • Santos-Caballero, Miriam
  • Qiu, Qiongju
  • Calvó-Tusell, Carla
  • Escriche, Celia
  • Turcu, Andreea L.
  • Prischi, Filippo
  • Bartra, Clara
  • Val, Cristina
  • Morisseau, Christophe
  • Pérez, Belén
  • Bertran-Mostazo, Andrea
  • Osuna, Sílvia
  • Corpas, Rubén
  • Griñán-Ferré, Christian
  • Galdeano, Carles
  • Loza, M Isabel
  • Pallàs, Mercè
  • Sanfeliu, Coral
  • Hammock, Bruce D.
  • Brea, José
  • Feixas, Ferran
  • Conte, Maria R.
  • Cobos, Enrique J.
  • Vázquez, Santiago
The soluble epoxide hydrolase (sEH) has recently emerged as a promising target for the treatment of several pain-related conditions. Herein, we report the design and synthesis of a peripherally restricted sEH inhibitor with high potency and good Drug Metabolism and Pharmacokinetics (DMPK) properties. Molecular dynamics and X-ray crystallography helped reveal the binding of these inhibitors to sEH. The selected compound showed a robust analgesic effect in a dose-dependent manner in a murine model of chemotherapy-induced neuropathic pain (CINP). Moreover, the compound also prevented the development of paclitaxel-induced neuropathic pain. Overall, these results suggest that peripheral inhibition of sEH might constitute a novel therapy to prevent and treat CINP., This work was funded by the Spanish Ministerio de Ciencia, Innovación y Universidades, MICIU/AEI/10.13039/501100011033: Grants PID2020-118127RB-I00 and PID2023-147004OB-I00 (to S.V.), PID2019-108691RB-I00 (to E.J.C.), PDC2021-121096 (to M.P. and C.S.), PID2021-127693OB-I00 (to C.G.), PID2022-141676NB-I00 (to F.F.); PID2021-129034NB-I00 and PDC2022-133950-I00 (to S.O.); the Generalitat de Catalunya (2021 SGR 00357 and 2021 SGR 00487); the European Research Council (ERC-2015-StG-679001-NetMoDEzyme and ERC-2022-CoG-101088032 to S.O.); the Xunta de Galicia (ED431C 2022/20); and the European Regional Development Fund (ERDF); Ministry of Science and Innovation, Spain, with funds from the European Union NextGenerationEU (PRTRC17.I1) and the Autonomous Community of Galicia within the framework of the 2023 Biotechnology Plan Applied to Health (to M.I.L. and J.B.). Partial support was provided by NIH-NIEHS River Award R35 ES030443 and, NIH-NIEHS Superfund Program P42 ES004699 to B.D.H. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. M.R.C. was granted access to I24 beamline by the Diamond Light Source for (proposal number: MX32787). S.C. and A.L.T. received PhD fellowships from the Universitat de Barcelona (APIF grant) and the Spanish Ministerio de Educación, Cultura y Deporte (FPU15/00889 grant), respectively. A.B.-M., C.E., and M.S.-C. were supported by the Research Personnel Training Program (FPI grants PRE2019-087468, PRE2022-104952, and PRE2020-096203, respectively) of the Spanish Ministerio de Ciencia, Innovación y Universidades (MICIU) and Agencia Estatal de Investigación (AEI). Q.Q. is funded by the King’s-China Scholarship Council PhD Scholarship programme. F.F. received Spanish MICINN for a Ramón y Cajal fellowship (RYC2020-029552-I). C.C.-T. received Science Postdoctoral Fellowship from a Schmidt Futures program., Peer reviewed